Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant factor VIIa does not induce hypercoagulability in vitro.

S Gallistl1, G Cvirn, W Muntean

  • 1Dept of Paediatrics, Ludwig Boltzmann Research Institute for Paediatric Haemostasis and Thrombosis, University of Graz, Austria. Siegfried.gallistl@kfunigraz.ac.at

Thrombosis and Haemostasis
|March 4, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response.

Scandinavian journal of rheumatology·2015
Same author

Regular smoking is not associated with increased thrombin generation in young adults.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Port-A-Cath infection causes inhibitor recurrence after initial successful ITI.

Haemophilia : the official journal of the World Federation of Hemophilia·2013
Same author

Normalization of haemostatic alterations in overweight children with weight loss due to lifestyle intervention.

Atherosclerosis·2011
Same author

[Is the DDAVP-test helpful to diagnose children?].

Hamostaseologie·2010
Same author

High microparticle concentration in cord plasma.

Hamostaseologie·2010

Recombinant factor VIIa (rVIIa) does not appear to induce hypercoagulability, unlike activated prothrombin complex concentrates. This study found no increase in free thrombin generation with rVIIa, suggesting a lower thrombotic risk.

Area of Science:

  • Hematology
  • Hemostasis and Thrombosis
  • Pharmacology

Background:

  • Recombinant factor VIIa (rVIIa) is used for hemophilia patients with inhibitors.
  • Thrombotic complications are a concern with activated prothrombin complex concentrates.
  • Free thrombin generation can indicate hypercoagulability.

Purpose of the Study:

  • To assess the pro-thrombotic potential of rVIIa in vitro.
  • To compare thrombin generation induced by rVIIa versus activated prothrombin complex concentrates.

Main Methods:

  • Assessed free thrombin and Xa generation in factor VIII and IX deficient plasma.
  • Extrinsic activation of rVIIa was used.
  • Supplementation with rVIIa and activated prothrombin complex concentrates was performed.

Related Experiment Videos

Main Results:

  • rVIIa (150 U/ml) significantly shortened clotting times in deficient plasmas.
  • No significant difference in free thrombin or Xa generation was observed with or without rVIIa.
  • Activated prothrombin complex concentrates markedly increased free thrombin generation in all plasmas.

Conclusions:

  • In vitro findings suggest rVIIa does not induce a hypercoagulable state.
  • rVIIa may pose a lower thrombotic risk compared to activated prothrombin complex concentrates.